

Table S1. Summary of study characteristics

	MSSA	MRSA	Other Staph	Strep	Enterobacteriales	Anaerobes	Enterococci	Pseudomonas	Other	All
Studies	27	29	27	69	58	24	43	21	54	352
Microbes	3460	522	352	153	965	77	412	109	168	6218
Country	1 was global						1 global			2 Global
N. America	4 (15%)	4 (14%)	3 (11%)	19 (28%)	8 (14%)	8 (33%)	8 (19%)	3 (14%)	13 (24%)	70 (20%)
S. America				18 (26%)		8 (33%)	5 (12%)	1 (5%)	14 (26%)	46 (13%)
Europe	17 (63%)	24 (83%)	20 (74%)	9 (13%)	31 (53%)	4 (17%)	17 (40%)	14 (67%)	15 (28%)	151 (43%)
Asia	5 (19%)	1 (3%)	4 (15%)	23 (33%)	19 (33%)	4 (17%)	12 (28%)	3 (14%)	12(22%)	83 (24%)
Year										
1950-1970	1 (4%)		1 (4%)							2 (0.6%)
1971-1980	1 (4%)				6 (10%)			2 (10%)		9 (2.6%)
1981-1990		1 (3%)								1 (0.3%)
1991-2000		4 (14%)		2 (3%)						6 (1.7%)
2001-2005	2 (7%)	3 (10%)	1 (4%)	4 (6%)	3 (5%)	6 (25%)	1 (2%)	1 (5%)	7 (13%)	28 (8%)
2005-2010	5 (19%)	7 (24%)	3 (11%)	1 (1%)	9 (16%)	1 (4%)	11 (26%)	6 (29%)	9 (17%)	52 (15%)
2011-2015	13 (48%)	10 (34%)	18 (67%)	15 (22%)	20 (34%)	1 (4%)	8 (19%)	6 (29%)	10 (19%)	101 (29%)
2016-2017	1 (4%)	1 (3%)		22 (32%)	1 (2%)	12 (50%)	12 (28%)	2 (10%)	17 (31%)	68 (19%)
2018-2019	3 (11%)	3 (10%)	4 (15%)	19 (28%)	7 (12%)	2 (8%)	6 (14%)	2 (10%)	8 (15%)	54 (15%)
2020-2021	1 (4%)			6 (9%)	12 (21%)	2 (8%)	5 (12%)	2 (10%)	3 (6%)	31 (9%)
PIV/CLHX	2/25	1/28	1/26	0/69	13/45	1/23	4/39	3/18	1/53	26/326 7%/93
Isolate nature (lab/clinical)	16/11	5/24	9/18	55/14	26/32	18/6	29/14	13/8	43/11	214/138 61%/39%
MDR	0	3 (10.3%)	0	0	6 (10%)	0	3 (7%)	2 (10%)	2 (4%)	16 (5%)
Mean Exposure Time	2066 (1261.53)	2312 (692.00)	3007 (1842.46)	1596 (598.53)	1980 (1213.90)	3243 (1721.82)	1913 (1051.75)	2080 (1376.37)	1973 (804.95)	2100 (1224.18)

Table S2. The number of experiments captured from the included studies, tabulated by the antiseptic studied and the family of the microbe

Family	Number of experiments	
	Chlorhexidine	Povidone iodine
Acinetobacter	6	0
Actinomyces	1	0
Anaerobes	10	1
Enterococci	19	2
Enteriobacteriales	24	13
Pseudomonas	12	3
Pyogenes (Group A, β -haemolytic) Streptococci	3	0
Viridans (Group B, α -haemolytic) Streptococci	22	0
Coagulase Negative Staphylococci	15	1
Staphylococcus aureus (unspecified)	3	0
Staphylococcus aureus (MRSA)	23	1
Staphylococcus aureus (MSSA)	13	2

Figure S1. Forest plot of the mean MBC for chlorhexidine, in different *Staphylococci*

